Online curriculum start: Delayed until late 2024
(we will inform you once program and schedule have been finalized)

Program Synopsis

Bone marrow failure (BMF) and predisposition to hematopoietic malignancies are a group of rare disorders with at least 150 genes known to be implicated in their etiology. Being rare disorders, evidence-based knowledge is limited and the diagnostic workup, clinical practice decisions as well as surveillance relies on expert knowledge gathered in large academic centers. Patient outcomes vary depending on how they are diagnosed and where they are treated. There is a need for improved and systematic education about these entities, given the limited access to specialized diagnostic tests as well therapies resulting in inferior patient outcomes.

Currently, there is no known published curriculum to teach physicians, advanced practice providers, or genetic counselors about these conditions.

Based on a needs assessment survey that we performed in 2019, we have developed a systematic curriculum on BMF and predisposition to hematopoietic malignancies, with the goal to increase competency in providing safe and optimal care for these patients.

Learning Goals

Create a systematic teaching course to teach BMF/ Heme malignancy predisposition to:

• Pediatric and adult hematology/oncology physicians (U.S. and worldwide) to improve clinical management
• Advanced practice providers in the U.S. to improve clinical management
• Genetic counselors certified via the American Board of Genetic Counselors or other national organization to improve diagnostic workup and counseling

Target Audience 

• Hematology/Oncology Fellows (Physicians)
• Advanced Practice Providers (Nurse Practitioners, Physician Assistants)
• Genetic Counselors

Topics

• Aplastic Anemia
• Pediatric MDS and Juvenile Myelomonocytic Leukemia
• Diamond Blackfan Anemia
• Fanconi Anemia
• Telomere Biology Disorders (Dyskeratosis Congenita)
• Severe Congenital Neutropenia and Shwachman Diamond Syndrome
• GATA2 Deficiency and SAMD9/9L Disorders
• Other syndromes predisposing to MDS/AML (RUNX1, DDX41, and others)
• Other syndromes predisposing to BMF (MECOM, DNAJC21, ERCC6L2, and others)
• Clonal Hematopoiesis of Indeterminate Potential 
• Predisposition to Lymphatic Malignancies (TP53 and others)

Tentative Curriculum Structure / Time Commitment

• Online Curriculum 
  • 13 interactive weekly seminars (Spring 2024 – Fall 2024)
  • Online assignments with discussion (1 hour preparation time is required for each module)
• Final virtual meeting (including course exam and meet-the-expert sessions). Date TBD.

Application Process

• The application portal will open in early 2024..
• Because our goal is to provide individual mentorship, the space will be limited
• After successful completion of the course, participants will receive a course certificate and CME/CEU points